Given the relative paucity of cytotoxic immune cells and immunosuppressive myeloid predominance despite radiotherapy in SB28, we hypothesized that combined IL-6 and PD-1 blockade, which increases T cell infiltration and reprograms the myeloid compartment in this preclinical model (Fig. 7), would promote immune activation in favor of tumor control. This evidence concerns the gene IL6 and neoplasm.